The biopharmaceutical industry is undergoing a significant transformation, with licensing agreements increasingly serving as the bedrock for pipeline expansion and market penetration. As these cross-border collaborations proliferate, particularly in the dynamic Asia-Pacific region, the traditional focus on scientific merit is being augmented by a critical new determinant: robust evidence of Chemistry, Manufacturing, and Controls (CMC) readiness. This operational imperative is rapidly becoming a decisive test of asset value and a cornerstone of deal confidence, fundamentally reshaping how biopharma assets are evaluated, transacted, and brought to market.
n
The days when groundbreaking science alone was sufficient to attract significant investment are evolving. While scientific innovation remains paramount, buyers and strategic partners now demand tangible proof that an asset can be seamlessly transferred, efficiently scaled, and reliably supplied without compromising its commercial potential. For assets where manufacturing is outsourced, the expertise and track record of the chosen Contract Development and Manufacturing Organization (CDMO) can dramatically bolster confidence in the technical, regulatory, and financial viability of the venture, directly linking CMC readiness to the asset’s overall valuation. This shift underscores a broader industry recognition: CMC is no longer a downstream technical hurdle but an integral, strategic component of asset development from its earliest stages.
n
The Evolving Landscape of Biopharma Growth Through Licensing
n
Biopharma licensing agreements represent a sophisticated mechanism for accelerating growth, sharing risk, and leveraging specialized expertise. In an out-licensing scenario, an innovator grants specific rights to another company, typically in exchange for an upfront payment, milestone payments tied to development and commercialization, and future royalties. This structure offers smaller developers vital access to capital, regulatory acumen, advanced manufacturing capacity, or expansive commercial reach, while concurrently distributing the substantial costs and inherent risks associated with advancing a therapeutic asset through its lifecycle.
n
Conversely, in-licensing involves a company acquiring rights to an external asset, thereby assuming responsibility for some or all of its continued development and commercialization. This strategy allows companies to fortify their pipelines far more rapidly than relying solely on internal discovery efforts. However, this expedited growth comes with its own set of challenges, as the licensee inherits not only the asset’s promise but also its existing technical, regulatory, and market-related risks.
n
The agreement itself is merely a singular point within a much longer, intricate process. Asset valuation and partner identification precede exhaustive data-room preparation, rigorous due diligence, complex negotiations, and the finalization of contracts. Crucially, the relationship extends far beyond the signing ceremony, encompassing ongoing development, regulatory submissions across multiple jurisdictions, manufacturing, and ultimately, market launch. Decisions made during the preclinical and early clinical stages, long before a deal is contemplated, can profoundly impact future costs, timelines, and the long-term resilience of the supply chain.
n
Chronology of a Paradigm Shift: Asia-Pacific’s Ascent and High-Stakes Deals
n
The strategic importance of Asia-Pacific, particularly China, as a burgeoning source of innovative biopharmaceutical assets, has profoundly accelerated this operational shift. GlobalData’s 2026 conference analysis revealed a striking trend: agreements where US biopharma companies in-licensed innovative drugs from China reached nearly 50% in 2025. This momentum continued into 2026, prominently showcased at the prestigious JP Morgan Healthcare Conference. During this event, industry giants announced multi-billion dollar deals, signifying the profound confidence placed in Asian innovation. AbbVie, for instance, unveiled a licensing agreement worth an astonishing $5.6 billion for RemeGen’s Phase II bispecific antibody RC148. Similarly, Novartis sealed a collaboration exceeding $1.6 billion with SciNeuro Pharmaceuticals for its promising Alzheimer’s disease candidates.
n
The allure of the Asia-Pacific market extends far beyond merely lower development costs. GlobalData’s comprehensive analysis points to several compelling advantages, including the potential for faster clinical trial execution, robust and rapidly advancing research capabilities, and a deeper, more diverse pipeline of highly differentiated therapies. This trend is not unidirectional; 2025 also saw significant out-licensing activity from the region, highlighted by GSK’s monumental $12.5 billion agreement with China’s Jiangsu Hengrui, underscoring the reciprocal flow of innovation and capital.
n
These increasingly complex, high-value cross-border deals inevitably amplify the critical importance of meticulous CMC due diligence. A prospective licensee must rigorously establish whether the clinical product can be consistently reproduced at the required commercial scale, whether the underlying data package is robust enough to support regulatory filings in all target markets, and whether the intricate manufacturing knowledge can be effectively and safely transferred across different companies, facilities, and diverse regulatory regions. In this intricate landscape, a knowledgeable CDMO, intimately familiar with the asset and its manufacturing journey, becomes an invaluable ally. They can empower prospective partners to thoroughly test their assumptions against concrete evidence pertaining to process robustness, existing capacity, and the specific regulatory landscape.
n
Supporting Data and Expert Insight: The Centrality of CMC Due Diligence
n
Financial models, the backbone of any investment decision, traditionally weigh revenue forecasts, projected development expenditures, intellectual property protection (patent life), competitive positioning, and the probability of both regulatory and commercial success. Critically, weak or uncertain manufacturing assumptions can adversely affect every single one of these inputs. Conversely, robust evidence demonstrating process robustness, a clear understanding of the cost of goods (COGS), confirmed manufacturing capacity, a well-defined technology transfer strategy, and clear regulatory readiness can significantly strengthen confidence in the fundamental assumptions underpinning the asset’s valuation.
n
CMC due diligence is a forensic examination, delving into whether the manufacturing process is fully understood and inherently scalable. It scrutinizes the suitability and validation status of analytical methods, assesses whether stability data adequately supports the proposed shelf life, and verifies that drug-substance and drug-product specifications are scientifically justified and achievable. Furthermore, it meticulously investigates potential impurities, degradation products, the robustness of quality systems, comprehensive batch history records, and all previous interactions with regulatory bodies. These probing questions can uncover potential liabilities that may not be immediately apparent from clinical data alone. More importantly, the evidence gathered during this process serves as a strategic input into the asset’s overarching technical, regulatory, and financial viability, transcending its role as a mere exercise in identifying manufacturing risk.
n
An immature manufacturing process, for example, may necessitate substantial additional development work before pivotal trials can commence, leading to significant delays and cost overruns. Incomplete stability studies can severely restrict supply chain planning and market access. Weak or poorly validated analytical methods can render it exceedingly difficult to demonstrate comparability after a critical manufacturing change, potentially stalling regulatory approval. Moreover, an unrealistic cost-of-goods assumption can fundamentally undermine the commercial viability of an otherwise promising therapy, regardless of its clinical efficacy.
n
A recent Thermo Fisher Scientific webinar explored these nuances in granular detail, advocating for the proactive development of an "audit-ready CMC package." Such a package, they recommended, should feature traceable, consistent data; compelling evidence of process robustness; early and comprehensive scale-up planning; and a clear, transparent narrative explaining what is known, what remains uncertain, and a well-defined strategy for addressing identified gaps. This proactive, transparent approach enables a prospective partner to clearly distinguish between manageable development work and fundamental risks that could either derail a program or necessitate a significant adjustment in valuation. Crucially, it also instills greater confidence in assumptions related to scalability, cost projections, available capacity, technology-transfer readiness, and the ultimate path to commercialization.
n
Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, unequivocally articulated the direct link between CMC due diligence and asset valuation. "The CMC package and due diligence act as a strategic gate to evaluate a variety of factors and the value of the asset," he emphasized, highlighting its pivotal role in the overarching deal framework.
n
The Indispensable Role of CDMOs in De-risking Transactions
n
CDMOs, with their extensive experience spanning development, technology transfer, regulatory filing, and commercial supply, are uniquely positioned to add substantial value across every phase of a biopharma transaction.
n
- n
- Before a Deal: Prior to formal due diligence, a CDMO can be instrumental in constructing a comprehensive, licensing-ready CMC package. They can proactively identify potential gaps, stress-test process robustness, and strengthen overall scale-up readiness, thereby enhancing the asset’s attractiveness and reducing pre-deal uncertainties.
- During Due Diligence: As diligence unfolds, the CDMO can provide critical support through technical assessments, independent audits, in-depth gap analyses, manufacturing feasibility studies, validation of cost and capacity assumptions, and expert guidance on complex regulatory considerations. Their objective insights provide a credible foundation for decision-making.
- After Signing: Post-acquisition, the same CDMO partner can seamlessly translate diligence findings into actionable remediation plans, execute efficient technology transfer, manage complex scale-up operations, provide ongoing regulatory support, and ultimately ensure a reliable commercial supply chain. This continuity connects assessment directly with execution, ensuring a smooth transition.
n
n
n
n
Thermo Fisher Scientific’s webinar provided a compelling case study: their support for an Asian biotech’s low-dose oncology tablet involved drug-product development, technology transfer, clinical manufacturing, and scale-up. During subsequent diligence by several prospective partners, the CDMO was audited, and its work underwent meticulous gap analysis. The outcome was a testament to the power of robust CMC execution: a global biopharma company ultimately acquired the asset in a deal valued at over $1 billion. This concrete example powerfully illustrates how strong CMC execution, underpinned by CDMO expertise, can directly drive transaction confidence and significantly enhance asset value.
n
Strategies for Maximizing Deal Success in a CMC-Centric Environment
n
Licensing teams can substantially improve their negotiation position and maximize deal success by proactively strengthening CMC readiness before formal due diligence commences, rather than viewing it merely as a reactive risk-mitigation exercise. This strategic approach begins with assembling an "audit-ready CMC package" – a meticulously organized compilation of process knowledge, validated analytical methods, comprehensive specifications, robust stability data, and detailed batch history, all presented in a consistent, traceable, and easily accessible format.
n
Crucially, this package should clearly delineate between issues that have been definitively resolved and any remaining development work that will be required. It should articulate precisely how critical quality attributes (CQAs) are controlled, present the evidence supporting process robustness, and outline a clear strategy for how the asset could be efficiently transferred to a new facility or manufacturing partner. Presenting these points transparently and early helps potential licensees accurately assess the scope of remaining work without automatically assuming that every perceived gap represents a fundamental weakness in the asset itself.
n
Furthermore, teams must meticulously account for practical considerations such as potential equipment differences between facilities, complex material sourcing strategies, comparability requirements following process changes, available manufacturing capacity, and the time required to complete any outstanding technical work. Responsibilities for these critical activities must be clearly assigned and agreed upon well before negotiations reach an advanced stage, distinguishing between tasks that must be completed pre-signing and those that can continue under the new partnership.
n
An experienced CDMO can significantly enhance this preparatory phase by independently challenging assumptions related to cost, timelines, process performance, and supply chain resilience. This independent validation can expose potential weaknesses before they escalate into contentious negotiating points, providing both parties with a more credible and mutually acceptable basis for asset valuation and risk allocation. After the deal is signed, the same trusted CDMO partner can then facilitate the seamless transition, translating diligence findings into concrete remediation plans, executing complex technology transfers, and managing the critical scale-up process, thus bridging the gap between assessment and successful execution.
n
Anil Kane succinctly summarized the essential preparation required: "Build a licensing-ready data package, including well-organised, audit-ready documentation." He also strongly advocated for prioritizing transparency, emphasizing that all development, manufacturing, and analytical information must be traceable, readily accessible, and consistently presented to foster trust and expedite the diligence process.
Official Responses and Broader Implications
The industry’s leading voices consistently echo the sentiment that while clinical performance will undeniably remain the principal driver of an asset’s prospects, a robust and well-articulated route from development to commercial supply significantly de-risks the entire venture. This operational clarity reduces uncertainty, improves confidence in execution, and ultimately facilitates both sides reaching terms that accurately reflect the asset’s true, holistic potential. The active engagement of CDMOs, therefore, moves beyond mere service provision to becoming strategic partners in value creation and risk mitigation.
The implications of this shift are far-reaching. For smaller biotechs, demonstrating CMC readiness early can be a crucial differentiator, attracting larger partners and securing more favorable deal terms. It necessitates earlier investment in manufacturing strategy and process development, even for companies primarily focused on R&D. For the CDMO industry, this trend translates into increased demand for comprehensive, integrated services, rewarding those who can offer end-to-end solutions, deep regulatory expertise across diverse markets, and a proven track record of successful technology transfer and commercial scale-up.
Ultimately, this paradigm shift towards integrating CMC readiness into the core of asset valuation and deal confidence represents a maturation of the biopharmaceutical industry. It acknowledges that bringing life-changing therapies to patients requires not only scientific brilliance but also operational excellence, meticulous planning, and robust manufacturing capabilities. By embracing this holistic approach, the industry can navigate the complexities of global licensing with greater assurance, accelerate the delivery of innovative medicines, and unlock the true potential of biopharmaceutical assets. CMC readiness and CDMO expertise are no longer just supporting functions; they are now central pillars of strategic success in the dynamic world of biopharma.
